Beyond KIR and NKG2A blockade: reprogramming NK-cell immunity in solid tumors

Area of Science:

• Immunology
• Cancer Biology
• Cellular Therapy

Background:

• Natural killer (NK) cells possess inherent cytotoxicity against transformed cells without prior sensitization.
• Therapeutic application of NK cells in solid tumors is limited by complex inhibitory signaling networks, primarily involving killer cell immunoglobulin-like receptors (KIRs) and the CD94/NKG2A axis.
• Tumors evade NK cell detection by manipulating HLA-I expression and exploiting the immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To review the mechanisms of NK cell suppression mediated by KIR and CD94/NKG2 signaling within the tumor microenvironment.
• To explore emerging combinatorial and personalized strategies for enhancing NK cell-based immunotherapies in solid tumors.

Main Methods:

• Review of existing literature on NK cell function, inhibitory receptors, and tumor immune evasion strategies.
• Analysis of the impact of the tumor microenvironment on NK cell activity.
• Examination of novel therapeutic approaches combining checkpoint modulation, NK cell engineering, and TME remodeling.

Main Results:

• Inhibitory KIR and CD94/NKG2 signaling, modulated by tumor HLA-I expression, restricts NK cell anti-tumor activity.
• The TME, characterized by hypoxia, metabolic stress, and immunosuppressive factors, further impairs NK cell infiltration, persistence, and function.
• Monotherapy targeting KIR or NKG2A has shown limited clinical efficacy in solid tumors.

Conclusions:

• The KIR- and CD94/NKG2-centered network represents a critical target and a framework for next-generation NK cell immunotherapies.
• Future strategies necessitate a multi-pronged approach, integrating checkpoint blockade, engineered NK cells with enhanced resilience, and TME-modulating interventions.
• Personalized and combinatorial therapies hold the potential to overcome NK cell suppression and realize their full therapeutic capacity in solid tumors.